Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1627470 | 0.81 | PI4KA (0.31) | PI4KAPI4K2BPI4K2API4KBXDH | |
| SCHEMBL8079826 | 0.74 | — | — | |
| SCHEMBL2733779 | 0.74 | KDM4E (0.33) | XDHLMNA | |
| SCHEMBL4058595 | 0.67 | — | — | |
| SCHEMBL3318704 | 0.67 | — | — | |
| SCHEMBL2258938 | 0.67 | — | — | |
| SCHEMBL536796 | 0.67 | — | — | |
| SCHEMBL2255870 | 0.64 | MEN1 (0.32) | — | |
| SCHEMBL7111328 | 0.64 | DYRK1A (0.33) | — | |
| SCHEMBL537482 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024094125-A1 | LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-05-10 | — | — | WO | claimed |
| US-11814407-B2 | Multiple coupling and oxidation method | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-11-14 | — | — | US | claimed |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-11-02 | — | — | US | claimed |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-10-26 | — | — | US | claimed |
| WO-2023167094-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | 国立大学法人大阪大学 | 2023-09-07 | — | — | WO | claimed |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF NATIONAL INSTITUTE OF HEALTH SCIENCES (JP) | 2023-04-20 | — | — | US | claimed |
| US-11566042-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | ZATA Pharmaceuticals, Inc (US) | 2023-01-31 | — | — | US | claimed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | claimed |
| EP-4108670-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| EP-4108262-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-12-28 | — | — | EP | claimed |
| US-5187174-A | Biological antigrowth agents | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-02-16 | — | — | US | claimed |
| US-5126347-A | Autoimmune deficiency syndrome | HOFFMANN-LA ROCHE INC. (US) | 1992-06-30 | — | — | US | claimed |
| US-4997928-A | DNA sequencing | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-03-05 | — | — | US | claimed |
| EP-0383531-A2 | 6'-deoxy-6'-halogenoneplanosin A and its production | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1990-08-22 | — | — | EP | claimed |
| EP-0383239-A1 | Isomeric dideoxynucleosides, their preparation and their use in medicaments | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-22 | — | — | EP | claimed |
| EP-0359225-A2 | Reagents for the preparation of 5'-tagged oligonucleotides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0339842-A2 | Novel oligoribonucleotide derivatives and application thereof to antiviral agents | ISIS PHARMACEUTICALS, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0285884-A2 | Process to produce 2', 3'-Dideoxynucleosides | Bristol-Myers Squibb Company (US) | 1988-10-12 | — | — | EP | claimed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | claimed |
| US-4605659-A | HERPES; HEPATITUS | SYNTEX (U.S.A.) INC. (US) | 1986-08-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566042-B2 | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds | PNKP, POLI, TYMP | PI4KA 473/4885PI4K2B 637/4885PI4K2A 541/4885 |
| US-20230340008-A1 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | SLC29A1, SLC29A2, PNP | PI4KA 3060/4885PI4K2B 2971/4885PI4K2A 3125/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | PI4KA 1223/4885PI4K2B 1251/4885PI4K2A 1161/4885 |
| US-11814407-B2 | Multiple coupling and oxidation method | RNGTT, PCNA, TYMP | PI4KA 984/4885PI4K2B 1137/4885PI4K2A 1168/4885 |
| US-20230124641-A1 | CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME | RNGTT, NUDT1, SLC29A2 | PI4KA 2206/4885PI4K2B 2055/4885PI4K2A 2161/4885 |
| US-20230348522-A1 | METHOD FOR PRODUCING BICYCLIC PHOSPHORAMIDITE | PFAS, ENPP1, NAAA | PI4KA 933/4885PI4K2B 771/4885PI4K2A 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.